Blincyto
| Name | Blincyto |
|---|---|
| Active Substance | blinatumomab |
| Prescription | na recept |
| Type of prescription | ograničeni recept |
| Distribution | u ljekarni |
| ATC Code | L01XC19 |
| Medicinal product marketed in the Croatia | Da |
| Link to the European Medicines Agency's (EMA) product information | download |
| Educational materials for healthcare professionals |
Vodič za liječnike, verzija 3 Vodič za ljekarnike, verzija 3 Vodič za medicinske sestre, verzija 3 |
| Educational materials for patients / caregivers |
Vodič za bolesnike i njegovatelje, verzija 3 Kartica za bolesnika, verzija 3 |
Note
The medicinal product has been authorised via centralised procedure in all Member States of the European Union based on the European Medicines Agency's expert opinion. Additional information on the medicinal product can be found under the following link:https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto
The marketing authorisation has been granted by the European Commission. All marketing authorisations of the European Commission can be found under the following link: http://ec.europa.eu/health/documents/community-register/html/index_en.htm
